WallStSmart

DexCom Inc (DXCM)vsENvue Medical Inc. (FEED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 227740% more annual revenue ($4.97B vs $2.18M). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 4.3Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

FEED

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -1.85

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

FEED2 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

DXCM3 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

P/E RatioValuation
35.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.9x4/10

Trading at 12.9x book value

FEED4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.72M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : FEED

The strongest argument for FEED centers on Price/Book, Debt/Equity.

Bear Case : DXCM

The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : FEED

The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

DXCM profiles as a mature stock while FEED is a value play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.41 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 30/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

ENvue Medical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

ENvue Medical Inc. (FEED) is a pioneering healthcare technology company that specializes in the development of cutting-edge medical devices and integrated software solutions aimed at enhancing patient care management. By leveraging innovation to optimize health outcomes and streamline recovery processes, ENvue is well-positioned to capitalize on substantial growth opportunities within the dynamic healthcare landscape. With a strong product pipeline and strategic collaborations, the company represents a compelling investment for institutional investors interested in the future of medical devices and digital health advancements.

Want to dig deeper into these stocks?